Kalicia Christie
Family · San Antonio, TXNPI 1033775572
Payments from drug & device makers
Across 1,106 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Mannkind Corporation$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Novartis$1K
- plus $10K from 47 others
What the payments were for
- Food & beverage$19,629100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$697
- FARXIGA$253
- FREESTYLE LIBRE 3$140
- DEXCOM G6 TRANSMITTER$122
How this compares
$19,672 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 376 | $481,971 |
| MounjaroTirzepatide | 330 | $387,623 |
| TrulicityDulaglutide | 137 | $207,622 |
| JardianceEmpagliflozin | 157 | $198,274 |
| AfrezzaInsulin Regular, Human | 52 | $168,929 |
| FarxigaDapagliflozin Propanediol | 119 | $139,241 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $109,242 |
| TymlosAbaloparatide | 26 | $72,283 |
| ProliaDenosumab | 36 | $59,842 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $52,244 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $45,430 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 17 | $42,094 |
| TradjentaLinagliptin | 37 | $38,177 |
| RybelsusSemaglutide | 24 | $37,097 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $34,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $1,749 | $626,943558 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $2,212 | $534,659437 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $1,197 | $264,701214 claims |
| Mannkind CorporationAfrezza | $1,603 | $168,92952 claims |
| AstraZenecaFarxiga | $1,376 | $139,241119 claims |
| AmgenProlia, Evenity (2 Syringes) | $865 | $101,93753 claims |
| Radius Health, Inc.Tymlos | $883 | $72,28326 claims |
| MerckJanuvia | $68 | $11,96915 claims |
| Cequr CorporationCequr Simplicity | $712 | $11,67925 claims |
| AbbVieSynthroid | $583 | $7,57286 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.